← Latest news 
Sun Pharma eyes funding swaps and offshore loans for 12 billion Organon deal approval
Business
Published on 6 May 2026
Lenders weigh turning Organon bondholders into Sun debt
Sun Pharmaceutical Industries is exploring multiple financing routes for its proposed $12 billion acquisition of Organon & Co. Reports say lenders are considering swapping Organon bondholders into Sun Pharma debt, including a possible euro-denominated bond, while Sun Pharma also plans to raise $3 billion to $4 billion in offshore loans. Deal approvals are expected by December.
- Lenders are reviewing several funding structures for the 12 billion acquisition
- Organon bondholders could be swapped into Sun Pharma debt
- Sun Pharma may issue euro-denominated bond financing as an option
- Offshore loans of 3 billion to 4 billion are planned ahead of December approvals
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times